ClinicalTrials.gg
CompletedNCT00717405Updated Aug 2, 2016Results posted

A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

A Phase 2 interventional study of Standard chemotherapy and bevacizumab [Avastin] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 28 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.

Enrollment
69th of 130
52 · median 58
Started
2008
with 23 others
Phase 2
89 of 131
6 open now
Registered
72nd of 131
by date
Lead sponsor
14 of 131
Hoffmann-La Roche

Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 69th largest by enrollment of the 130 interventional ones that give a count, is one of 24 that started in 2008, is one of 89 in phase 2, and was the 72nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing bevacizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of preoperative treatment with Avastin combined with Herceptin-based chemotherapy in patients with primary inflammatory HER2-positive breast cancer. Patients will be treated with a total of 8 cycles of pre-operative chemotherapy + Avastin + Herceptin. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult females, >=18 years of age;
  • inflammatory breast cancer;
  • -positive tumors;
  • performance status 0-2.

Exclusion criteria

Exclusion Criteria:

  • ;
  • previous treatment with chemotherapy, radiation therapy or hormone therapy for a breast tumor;
  • cardiovascular disease, or history of thrombotic disorders.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    1

    Drug: Standard chemotherapy · Drug: bevacizumab [Avastin] · Drug: trastuzumab [Herceptin]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification

    PCR was assessed at the time of definitive surgery according to Sataloff classification and centrally reviewed by an independent committee under blinded conditions. Pathological response was defined based on the therapeutic response at the primary tumor site and axillary lymph nodes. Primary tumor response criteria were as follows: T-A (Total / near total therapeutic effect), T-B (Subjectively greater than \[\>\] 50 percent \[%\] therapeutic effect but less than \[\<\] T-A), T-C (\<50% therapeutic effect, but effect evident), T-D (No therapeutic effect). Axillary lymph node response: N-A (Evidence of therapeutic effect, no metastases), N-B (No therapeutic effect, no nodal metastases), N-C (Nodal metastasis but evident therapeutic effect), N-D (Nodal metastasis with no therapeutic effect). T-A and N-A or T-A and N-B responses were defined as PCR and all other tumor responses as non-responders. Participants with missing values were considered as non-responders.

    Time frame: From baseline through Week 25 (Up to 6 months)

Secondary outcomes

  1. Percentage of Participants With a PCR According to the Chevallier Classification

    PCR was assessed at the time of definitive surgery according to Chevallier classification and centrally reviewed by an independent committee under blinded conditions. The Chevallier classification for grading of therapeutic effect related to the primary tumor site and axillary lymph nodes was defined by microscopic changes as follows - Grade 1: Disappearance of all tumors either in the breast or in the nodes, Grade 2: Persistence of carcinoma in situ in the breast only and no nodal invasion, Grade 3: Presence of invasive carcinoma with stromal alteration, Grade 4: Presence of invasive carcinoma without modification. Grade 1 response was considered as PCR. Participants with missing values were considered as non-responders.

    Time frame: From baseline through Week 25 (Up to 6 months)

  2. Percentage of Participants Who Were Responders Based on Inflammatory Signs From Baseline at Cycle 5 and Final Treatment Visit

    Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on inflammatory signs at Cycle 5 and final treatment visit were presented.

    Time frame: Baseline, Cycle 5 (Week 15), Neo-adjuvant treatment final visit (Week 25)

  3. Percentage of Participants Who Were Responders Based on Overall Clinical Response From Baseline at Cycle 5 and Final Treatment Visit

    Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on overall clinical response at Cycle 5 and final treatment visit were presented.

    Time frame: Baseline, Cycle 5 (Week 15), Neo-adjuvant treatment final visit (Week 25)

  4. Number of Participants Who Underwent Mastectomy

    Surgery included a mastectomy with axillary node dissection and had to be performed at least 4 weeks after the last infusion of neoadjuvant bevacizumab treatment.

    Time frame: Anytime between Week 26 and Week 29

  5. Percentage of Participants With Macroscopically Visible Tumor

    Local pathologists assessed the tumor whether it was macroscopically visible or not and percentage of participants for whom the tumor was macroscopically visible was reported.

    Time frame: Anytime between Week 26 and Week 29

  6. Percentage of Participants Who Underwent Lymph Node Resection

    Among the participants who were planned to undergo mastectomy, lymph node resection was also performed by the physician depending up on the participant's breast cancer grades.

    Time frame: Anytime between Week 26 and Week 29

  7. Breast Cancer Marker CA15.3 at Baseline, Neoadjuvant Final Visit and Change From Baseline at Neoadjuvant Final Visit

    Time frame: Baseline, Neoadjuvant Final Visit (Week 25)

  8. Percentage of Participants Who Were Disease Free at 3 and 5 Years

    A participant was considered disease free if the participant did not experience any of the following events: local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, colon carcinoma in situ, or lobular carcinoma in situ of the breast), or death from any cause.

    Time frame: 3, 5 years

  9. Disease Free Survival (DFS) Duration

    DFS was estimated using Kaplan-Meier method.

    Time frame: Up to 5 Years

  10. Percentage of Participants Who Were Recurrence Free at 3 and 5 Years

    A participant was considered recurrence free if the participant did not experience local or regional recurrence (wall or axillaries nodes), or occurrence of distant metastases (including soft tissue and distal lymph nodes).

    Time frame: 3, 5 years

  11. Recurrence Free Survival (RFS) Duration

    RFS was estimated using Kaplan-Meier method.

    Time frame: Up to 5 Years

  12. Percentage of Participants Who Were Alive at 3 and 5 Years

    Time frame: 3, 5 years

  13. Overall Survival (OS) Duration

    OS was defined as the time from the first administration of neoadjuvant treatment to death of any cause. OS was estimated using Kaplan-Meier method.

    Time frame: Up to 5 years

07

Results

Posted Jan 6, 2016

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + Trastuzumab Chemotherapy
Started52
Completed52
Not completed0

Outcome measures

PrimaryPercentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification

PCR was assessed at the time of definitive surgery according to Sataloff classification and centrally reviewed by an independent committee under blinded conditions. Pathological response was defined based on the therapeutic response at the primary tumor site and axillary lymph nodes. Primary tumor response criteria were as follows: T-A (Total / near total therapeutic effect), T-B (Subjectively greater than \[\>\] 50 percent \[%\] therapeutic effect but less than \[\<\] T-A), T-C (\<50% therapeutic effect, but effect evident), T-D (No therapeutic effect). Axillary lymph node response: N-A (Evidence of therapeutic effect, no metastases), N-B (No therapeutic effect, no nodal metastases), N-C (Nodal metastasis but evident therapeutic effect), N-D (Nodal metastasis with no therapeutic effect). T-A and N-A or T-A and N-B responses were defined as PCR and all other tumor responses as non-responders. Participants with missing values were considered as non-responders.

Time frame:
From baseline through Week 25 (Up to 6 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification
percentage of participantsBevacizumab + Trastuzumab
Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification63.46 (49.41 to 77.51)
SecondaryPercentage of Participants With a PCR According to the Chevallier Classification

PCR was assessed at the time of definitive surgery according to Chevallier classification and centrally reviewed by an independent committee under blinded conditions. The Chevallier classification for grading of therapeutic effect related to the primary tumor site and axillary lymph nodes was defined by microscopic changes as follows - Grade 1: Disappearance of all tumors either in the breast or in the nodes, Grade 2: Persistence of carcinoma in situ in the breast only and no nodal invasion, Grade 3: Presence of invasive carcinoma with stromal alteration, Grade 4: Presence of invasive carcinoma without modification. Grade 1 response was considered as PCR. Participants with missing values were considered as non-responders.

Time frame:
From baseline through Week 25 (Up to 6 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a PCR According to the Chevallier Classification
percentage of participantsBevacizumab + Trastuzumab
Percentage of Participants With a PCR According to the Chevallier Classification53.85 (39.34 to 68.36)
SecondaryPercentage of Participants Who Were Responders Based on Inflammatory Signs From Baseline at Cycle 5 and Final Treatment Visit

Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on inflammatory signs at Cycle 5 and final treatment visit were presented.

Time frame:
Baseline, Cycle 5 (Week 15), Neo-adjuvant treatment final visit (Week 25)
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Responders Based on Inflammatory Signs From Baseline at Cycle 5 and Final Treatment Visit
percentage of participantsBevacizumab + Trastuzumab
Response from baseline at Week 15 (n=43)88.4
Response from baseline at Week 25 (n=42)100.0
SecondaryPercentage of Participants Who Were Responders Based on Overall Clinical Response From Baseline at Cycle 5 and Final Treatment Visit

Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on overall clinical response at Cycle 5 and final treatment visit were presented.

Time frame:
Baseline, Cycle 5 (Week 15), Neo-adjuvant treatment final visit (Week 25)
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Responders Based on Overall Clinical Response From Baseline at Cycle 5 and Final Treatment Visit
percentage of participantsBevacizumab + Trastuzumab
Response from baseline at Week 15 (n=44)90.9
Response from baseline at Week 25 (n=45)97.8
SecondaryNumber of Participants Who Underwent Mastectomy

Surgery included a mastectomy with axillary node dissection and had to be performed at least 4 weeks after the last infusion of neoadjuvant bevacizumab treatment.

Time frame:
Anytime between Week 26 and Week 29
Reported as:
Number · participants
Number of Participants Who Underwent Mastectomy
participantsBevacizumab + Trastuzumab
Number of Participants Who Underwent Mastectomy49
SecondaryPercentage of Participants With Macroscopically Visible Tumor

Local pathologists assessed the tumor whether it was macroscopically visible or not and percentage of participants for whom the tumor was macroscopically visible was reported.

Time frame:
Anytime between Week 26 and Week 29
Reported as:
Number · percentage of participants
Percentage of Participants With Macroscopically Visible Tumor
percentage of participantsBevacizumab + Trastuzumab
Percentage of Participants With Macroscopically Visible Tumor26.5
SecondaryPercentage of Participants Who Underwent Lymph Node Resection

Among the participants who were planned to undergo mastectomy, lymph node resection was also performed by the physician depending up on the participant's breast cancer grades.

Time frame:
Anytime between Week 26 and Week 29
Reported as:
Number · percentage of participants
Percentage of Participants Who Underwent Lymph Node Resection
percentage of participantsBevacizumab + Trastuzumab
Percentage of Participants Who Underwent Lymph Node Resection98.0
SecondaryBreast Cancer Marker CA15.3 at Baseline, Neoadjuvant Final Visit and Change From Baseline at Neoadjuvant Final Visit
Time frame:
Baseline, Neoadjuvant Final Visit (Week 25)
Reported as:
Mean · Units per milliliter (U/mL)
Breast Cancer Marker CA15.3 at Baseline, Neoadjuvant Final Visit and Change From Baseline at Neoadjuvant Final Visit
Units per milliliter (U/mL)Bevacizumab + Trastuzumab
Baseline (n=52)39.66 ± 79.49
Neoadjuvant final visit (n=37)29.39 ± 10.06
Change in CA15.3 at neoadjuvant final visit (n=37)-3.39 ± 33.05
SecondaryPercentage of Participants Who Were Disease Free at 3 and 5 Years

A participant was considered disease free if the participant did not experience any of the following events: local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, colon carcinoma in situ, or lobular carcinoma in situ of the breast), or death from any cause.

Time frame:
3, 5 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Disease Free at 3 and 5 Years
percentage of participantsBevacizumab + Trastuzumab
3 years66.7 (52.0 to 77.8)
5 years60.8 (46.1 to 72.7)
SecondaryDisease Free Survival (DFS) Duration

DFS was estimated using Kaplan-Meier method.

Time frame:
Up to 5 Years
Reported as:
Median · months
Disease Free Survival (DFS) Duration
monthsBevacizumab + Trastuzumab
Disease Free Survival (DFS) DurationNA (NA to NA)
SecondaryPercentage of Participants Who Were Recurrence Free at 3 and 5 Years

A participant was considered recurrence free if the participant did not experience local or regional recurrence (wall or axillaries nodes), or occurrence of distant metastases (including soft tissue and distal lymph nodes).

Time frame:
3, 5 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Recurrence Free at 3 and 5 Years
percentage of participantsBevacizumab + Trastuzumab
3 years69.7 (54.8 to 80.5)
5 years65.4 (50.4 to 76.9)
SecondaryRecurrence Free Survival (RFS) Duration

RFS was estimated using Kaplan-Meier method.

Time frame:
Up to 5 Years
Reported as:
Median · months
Recurrence Free Survival (RFS) Duration
monthsBevacizumab + Trastuzumab
Recurrence Free Survival (RFS) DurationNA (NA to NA)
SecondaryPercentage of Participants Who Were Alive at 3 and 5 Years
Time frame:
3, 5 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Alive at 3 and 5 Years
percentage of participantsBevacizumab + Trastuzumab
Alive at 3 years90.0 (77.6 to 95.7)
Alive at 5 years81.8 (67.9 to 90.1)
SecondaryOverall Survival (OS) Duration

OS was defined as the time from the first administration of neoadjuvant treatment to death of any cause. OS was estimated using Kaplan-Meier method.

Time frame:
Up to 5 years
Reported as:
Median · months
Overall Survival (OS) Duration
monthsBevacizumab + Trastuzumab
Overall Survival (OS) DurationNA (NA to NA)

Adverse events

Collected over From Baseline until end of study (Up to approximately 6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Trastuzumab—20/52 (38.5%)52/52 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventBevacizumab + Trastuzumab
Febrile neutropeniaBlood and lymphatic system disorders6/52
LeukopeniaBlood and lymphatic system disorders6/52
Febrile bone marrow aplasiaBlood and lymphatic system disorders5/52
Impaired healingGeneral disorders3/52
Anal abscessInfections and infestations2/52
Ejection fraction decreasedInvestigations2/52
VomitingGastrointestinal disorders1/52
HyperthermiaGeneral disorders1/52
MalaiseGeneral disorders1/52
PyrexiaGeneral disorders1/52
Most frequent other events
Showing 10 of 84
Most frequent other events
EventBevacizumab + Trastuzumab
AstheniaGeneral disorders41/52
NauseaGastrointestinal disorders36/52
AlopeciaSkin and subcutaneous tissue disorders36/52
Mucosal inflammationGeneral disorders34/52
EpistaxisRespiratory, thoracic and mediastinal disorders33/52
ProteinuriaRenal and urinary disorders32/52
NeutropeniaBlood and lymphatic system disorders24/52
HypertensionVascular disorders21/52
Radiation skin injuryInjury, poisoning and procedural complications19/52
VomitingGastrointestinal disorders18/52

Baseline characteristics

Intent to treat population (ITT): Included all enrolled participants who had at least 1 post baseline assessment.

Age, Continuous
Age, Continuous(years)Bevacizumab + Trastuzumab
Mean51.48 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Trastuzumab
Female52
Male0
08

Study locations

28 sites
  • Besancon, 25030, France
  • Bordeaux, 33000, France
  • Brest, 29609, France
  • Caen, 14076, France
  • Clermont Ferrand, 63011, France
  • Dijon, 21079, France
  • La Tronche, 38700, France
  • Lille, 59020, France
  • Lyon, 69373, France
  • Marseille, 13273, France
  • Montpellier, 34298, France
  • Nantes, 44202, France
  • Nice, 06189, France
  • Paris, 75231, France
  • Paris, 75475, France
  • Paris, 75970, France
  • Reims CEDEX, 51056, France
  • Rennes, 35042, France
  • Rouen, 76038, France
  • Saint Brieuc, 22015, France
  • Saint Herblain, 44805, France
  • St Cloud, 92210, France
  • St Priest En Jarez, 42271, France
  • Strasbourg, 67065, France
  • Strasbourg, 67098, France
  • Toulouse, 31059, France
  • Vandoeuvre Les Nancy, 54511, France
  • Villejuif, 94805, France
09

References and documents

Publications

  • Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roche H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol. 2012 Apr;13(4):375-84. doi: 10.1016/S1470-2045(12)70049-9. Epub 2012 Feb 28. PubMed 22377126 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Apr 2010 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2008
First posted
Jul 17, 2008
Start
Oct 2008
Primary completionActual
Apr 2010
CompletionActual
Oct 2014
Results first posted
Jan 6, 2016
Last update
Aug 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00717405
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 17, 2008
Start date
Oct 2008
Primary completion
Apr 2010
Completion
Oct 2014
Results posted
Jan 6, 2016
Last update
Aug 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Trastuzumab

Start the discussion